{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:22:19Z","timestamp":1786980139576,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00415-023-11681-7","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T22:02:42Z","timestamp":1680645762000},"page":"3492-3498","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Long-term outcome of patients with neurological form of Wilson\u2019s disease compliant to the de-coppering treatment"],"prefix":"10.1007","volume":"270","author":[{"given":"Iva","family":"Stankovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u010carna","family":"Jovanovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Vitkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Svetel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Pekmezovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Tomi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2788-506X","authenticated-orcid":false,"given":"Nikola","family":"Kresojevi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladana","family":"Markovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milica","family":"Je\u010dmenica Luki\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Petrovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Draga\u0161evi\u0107-Mi\u0161kovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Kosti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"11681_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1474-4422(14)70190-5","volume":"14","author":"O Bandmann","year":"2015","unstructured":"Bandmann O, Weiss KH, Kaler SG (2015) Wilson\u2019s disease and other neurological copper disorders. Lancet Neurol 14:103\u2013113. https:\/\/doi.org\/10.1016\/S1474-4422(14)70190-5","journal-title":"Lancet Neurol"},{"issue":"1028\u20131035","key":"11681_CR2","doi-asserted-by":"publisher","first-page":"e1021","DOI":"10.1016\/j.cgh.2013.03.012","volume":"11","author":"KH Weiss","year":"2013","unstructured":"Weiss KH et al (2013) Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol 11(1028\u20131035):e1021-1022. https:\/\/doi.org\/10.1016\/j.cgh.2013.03.012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"11681_CR3","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.parkreldis.2011.05.002","volume":"17","author":"JF Burke","year":"2011","unstructured":"Burke JF et al (2011) Prognostic significance of neurologic examination findings in Wilson disease. Parkinsonism Relat Disord 17:551\u2013556. https:\/\/doi.org\/10.1016\/j.parkreldis.2011.05.002","journal-title":"Parkinsonism Relat Disord"},{"key":"11681_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41572-018-0018-3","volume":"4","author":"A Czlonkowska","year":"2018","unstructured":"Czlonkowska A et al (2018) Wilson disease. Nat Rev Dis Primers 4:21. https:\/\/doi.org\/10.1038\/s41572-018-0018-3","journal-title":"Nat Rev Dis Primers"},{"key":"11681_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1468-1331.2009.02607.x","volume":"16","author":"M Svetel","year":"2009","unstructured":"Svetel M et al (2009) Long-term outcome in Serbian patients with Wilson disease. Eur J Neurol 16:852\u2013857. https:\/\/doi.org\/10.1111\/j.1468-1331.2009.02607.x","journal-title":"Eur J Neurol"},{"key":"11681_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000070858","volume":"50","author":"MT Pellecchia","year":"2003","unstructured":"Pellecchia MT et al (2003) Clinical presentation and treatment of Wilson\u2019s disease: a single-centre experience. Eur Neurol 50:48\u201352. https:\/\/doi.org\/10.1159\/000070858","journal-title":"Eur Neurol"},{"key":"11681_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.parkreldis.2018.01.007","volume":"49","author":"H Hefter","year":"2018","unstructured":"Hefter H, Tezayak O, Rosenthal D (2018) Long-term outcome of neurological Wilson\u2019s disease. Parkinsonism Relat Disord 49:48\u201353. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.01.007","journal-title":"Parkinsonism Relat Disord"},{"key":"11681_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/qjmed\/hci095","volume":"98","author":"LK Prashanth","year":"2005","unstructured":"Prashanth LK et al (2005) Prognostic factors in patients presenting with severe neurological forms of Wilson\u2019s disease. QJM 98:557\u2013563. https:\/\/doi.org\/10.1093\/qjmed\/hci095","journal-title":"QJM"},{"key":"11681_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/00005792-199205000-00004","volume":"71","author":"GJ Brewer","year":"1992","unstructured":"Brewer GJ, Yuzbasiyan-Gurkan V (1992) Wilson disease. Medicine (Baltimore) 71:139\u2013164. https:\/\/doi.org\/10.1097\/00005792-199205000-00004","journal-title":"Medicine (Baltimore)"},{"key":"11681_CR10","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/mds.22231","volume":"24","author":"A Aggarwal","year":"2009","unstructured":"Aggarwal A, Aggarwal N, Nagral A, Jankharia G, Bhatt M (2009) A novel Global Assessment Scale for Wilson\u2019s Disease (GAS for WD). Mov Disord 24:509\u2013518. https:\/\/doi.org\/10.1002\/mds.22231","journal-title":"Mov Disord"},{"key":"11681_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12883-018-1039-y","volume":"18","author":"A Czlonkowska","year":"2018","unstructured":"Czlonkowska A et al (2018) Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson\u2019s Disease Rating Scale. BMC Neurol 18:34. https:\/\/doi.org\/10.1186\/s12883-018-1039-y","journal-title":"BMC Neurol"},{"key":"11681_CR12","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1002\/mds.23608","volume":"26","author":"M Svetel","year":"2011","unstructured":"Svetel M et al (2011) Quality of life in patients with treated and clinically stable Wilson\u2019s disease. Mov Disord 26:1503\u20131508. https:\/\/doi.org\/10.1002\/mds.23608","journal-title":"Mov Disord"},{"key":"11681_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.parkreldis.2009.01.010","volume":"15","author":"M Svetel","year":"2009","unstructured":"Svetel M et al (2009) Neuropsychiatric aspects of treated Wilson\u2019s disease. Parkinsonism Relat Disord 15:772\u2013775. https:\/\/doi.org\/10.1016\/j.parkreldis.2009.01.010","journal-title":"Parkinsonism Relat Disord"},{"key":"11681_CR14","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1007\/s12035-021-02525-4","volume":"58","author":"J Kalita","year":"2021","unstructured":"Kalita J, Kumar V, Parashar V, Misra UK (2021) Neuropsychiatric Manifestations of Wilson Disease: correlation with MRI and Glutamate Excitotoxicity. Mol Neurobiol 58:6020\u20136031. https:\/\/doi.org\/10.1007\/s12035-021-02525-4","journal-title":"Mol Neurobiol"},{"key":"11681_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.parkreldis.2022.01.016","volume":"95","author":"GR Palmieri","year":"2022","unstructured":"Palmieri GR et al (2022) Prevalence and features of non-motor symptoms in Wilson\u2019s disease. Parkinsonism Relat Disord 95:103\u2013106. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.01.016","journal-title":"Parkinsonism Relat Disord"},{"key":"11681_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/mds.1118","volume":"16","author":"M Svetel","year":"2001","unstructured":"Svetel M et al (2001) Dystonia in Wilson\u2019s disease. Mov Disord 16:719\u2013723. https:\/\/doi.org\/10.1002\/mds.1118","journal-title":"Mov Disord"},{"key":"11681_CR17","doi-asserted-by":"publisher","first-page":"875694","DOI":"10.3389\/fgene.2022.875694","volume":"13","author":"H Hou","year":"2022","unstructured":"Hou H et al (2022) Clinical and genetic analysis in neurological wilson\u2019s disease patients with neurological worsening following chelator therapy. Front Genet 13:875694. https:\/\/doi.org\/10.3389\/fgene.2022.875694","journal-title":"Front Genet"},{"key":"11681_CR18","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1007\/s10072-020-05013-0","volume":"42","author":"B Samanci","year":"2021","unstructured":"Samanci B et al (2021) Neurological features and outcomes of Wilson\u2019s disease: a single-center experience. Neurol Sci 42:3829\u20133834. https:\/\/doi.org\/10.1007\/s10072-020-05013-0","journal-title":"Neurol Sci"},{"key":"11681_CR19","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/hep.30280","volume":"69","author":"P Ferenci","year":"2019","unstructured":"Ferenci P et al (2019) Age and sex but Not ATP7B genotype effectively influence the clinical phenotype of Wilson disease. Hepatology 69:1464\u20131476. https:\/\/doi.org\/10.1002\/hep.30280","journal-title":"Hepatology"},{"key":"11681_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2011.08.028","volume":"312","author":"T Litwin","year":"2012","unstructured":"Litwin T, Gromadzka G, Czlonkowska A (2012) Gender differences in Wilson\u2019s disease. J Neurol Sci 312:31\u201335. https:\/\/doi.org\/10.1016\/j.jns.2011.08.028","journal-title":"J Neurol Sci"},{"key":"11681_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11011-013-9378-2","volume":"28","author":"T Litwin","year":"2013","unstructured":"Litwin T, Gromadzka G, Czlonkowska A, Golebiowski M, Poniatowska R (2013) The effect of gender on brain MRI pathology in Wilson\u2019s disease. Metab Brain Dis 28:69\u201375. https:\/\/doi.org\/10.1007\/s11011-013-9378-2","journal-title":"Metab Brain Dis"},{"key":"11681_CR22","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/S1474-4422(11)70232-0","volume":"10","author":"J Phukan","year":"2011","unstructured":"Phukan J, Albanese A, Gasser T, Warner T (2011) Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol 10:1074\u20131085. https:\/\/doi.org\/10.1016\/S1474-4422(11)70232-0","journal-title":"Lancet Neurol"},{"key":"11681_CR23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/jnnp.2003.026310","volume":"75","author":"LK Prashanth","year":"2004","unstructured":"Prashanth LK, Taly AB, Sinha S, Arunodaya GR, Swamy HS (2004) Wilson\u2019s disease: diagnostic errors and clinical implications. J Neurol Neurosurg Psychiatry 75:907\u2013909. https:\/\/doi.org\/10.1136\/jnnp.2003.026310","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11681_CR24","first-page":"642","volume":"81","author":"J Hu","year":"2001","unstructured":"Hu J, Lu D, Wang G (2001) Study on the clinical misdiagnosis of hepatolenticular degeneration. Zhonghua Yi Xue Za Zhi 81:642\u2013644","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"11681_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.parkreldis.2016.01.024","volume":"24","author":"R Dubbioso","year":"2016","unstructured":"Dubbioso R et al (2016) Subclinical neurological involvement does not develop if Wilson\u2019s disease is treated early. Parkinsonism Relat Disord 24:15\u201319. https:\/\/doi.org\/10.1016\/j.parkreldis.2016.01.024","journal-title":"Parkinsonism Relat Disord"},{"key":"11681_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.jhep.2011.11.007","volume":"56","author":"European Association for Study of L","year":"2012","unstructured":"European Association for Study of L (2012) EASL clinical practice guidelines: Wilson\u2019s disease. J Hepatol 56:671\u2013685. https:\/\/doi.org\/10.1016\/j.jhep.2011.11.007","journal-title":"J Hepatol"},{"key":"11681_CR27","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1097\/MPG.0000000000001700","volume":"65","author":"A Wiernicka","year":"2017","unstructured":"Wiernicka A et al (2017) Early onset of Wilson disease: diagnostic challenges. J Pediatr Gastroenterol Nutr 65:555\u2013560. https:\/\/doi.org\/10.1097\/MPG.0000000000001700","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"11681_CR28","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/s0168-8278(01)00219-7","volume":"35","author":"K Caca","year":"2001","unstructured":"Caca K et al (2001) High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol 35:575\u2013581. https:\/\/doi.org\/10.1016\/s0168-8278(01)00219-7","journal-title":"J Hepatol"},{"key":"11681_CR29","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/mds.20671","volume":"21","author":"G Gromadzka","year":"2006","unstructured":"Gromadzka G et al (2006) p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson\u2019s disease. Mov Disord 21:245\u2013248. https:\/\/doi.org\/10.1002\/mds.20671","journal-title":"Mov Disord"},{"key":"11681_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/ene.12348","volume":"21","author":"A Czlonkowska","year":"2014","unstructured":"Czlonkowska A et al (2014) D-penicillamine versus zinc sulfate as first-line therapy for Wilson\u2019s disease. Eur J Neurol 21:599\u2013606. https:\/\/doi.org\/10.1111\/ene.12348","journal-title":"Eur J Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11681-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-11681-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-11681-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T12:03:15Z","timestamp":1686744195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-11681-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["11681"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-11681-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marina Svetel, Nikola Kresojevi\u0107, Milica Je\u010dmenica Luki\u0107, Igor Petrovi\u0107, Nata\u0161a Draga\u0161evi\u0107-Mi\u0161kovi\u0107, have received a speaker honorarium from Salveo. Iva Stankovi\u0107, \u010carna Jovanovi\u0107, Jelena Vitkovi\u0107, Tatjana Pekmezovi\u0107, Aleksandra Tomi\u0107, Vladana Markovi\u0107 and Vladimir Kosti\u0107 have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}